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Abstract
Background: Minimising antimicrobial overuse is needed to limit antimicrobial resistance. There is little evidence
on how often microbiological testing informs antimicrobial de-escalation (e.g. stopping, shortening duration, switching
to narrower spectrum or intravenous to oral switch) at 48–72 h “review and revise”. We performed a patient level
analysis of diagnostic microbiology and antimicrobial prescribing to determine the impact of microbiology results on
antimicrobial review outcomes.
Methods: Antimicrobial prescribing data were collected for hospitalised adults from across Brighton and Sussex
University Hospitals NHS Trust using routine monthly audits of prescribing practice from July 2016 to April 2017.
Microbiology testing data for cultures of blood, urine, sputum and cerebrospinal fluid (CSF) were gathered from the
hospital pathology database and linked to prescriptions with matching patient identification codes. Antimicrobial
prescriptions were grouped into “prescription episodes” (PEs), defined as one or more antimicrobials prescribed to the
same patient for the same indication. Medical records were reviewed for all PEs with positive microbiology and a
randomised sample of those with negative results to assess the impact of the microbiology result on the antimicrobial
prescription(s).
Results: After excluding topical and prophylactic prescriptions, data were available for 382 inpatient antimicrobial
prescriptions grouped into 276 prescription episodes. 162/276 (59%) had contemporaneous microbiology sent. After
filtering likely contaminants, 33/276 (12%) returned relevant positive results, of which 20/33 (61%) had antimicrobials
changed from empiric therapy as a result with 6/33 (18%) prompting de-escalation. Positive blood and CSF tended to
have greater impact than urine or sputum cultures. 124/276 (45%) PEs returned only negative microbiology, and this
was documented in the medical notes less often (9/40, 23%) than positive results (28/33, 85%). Out of 40 reviewed PEs
with negative microbiology, we identified just one (~ 3%) in which antimicrobials were unambiguously de-escalated
following the negative result.
Conclusions: The majority of diagnostic microbiology tests sent to inform clinical management yielded negative
results. However, negative microbiology contributed little to clinical decision making about antimicrobial de-escalation,
perhaps reflecting a lack of trust in negative results by treating clinicians. Improving the negative predictive value of
currently available diagnostic microbiology could help hospital prescribers in de-escalating antimicrobial therapy.
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Introduction
Reducing antimicrobial over prescribing is key to miti-
gating the threat of antimicrobial resistance [1, 2]. While
hospital use accounts for < 20% of prescribed antimicro-
bials in most advanced healthcare systems, around two-
thirds of prescriptions for ‘broad-spectrum’ agents are
made in this setting [3]. Hospital clinicians prioritise
anticipated benefits of starting empiric antimicrobial
therapy when infection may be present over risks of
antimicrobial exposure. Controlling overuse depends on
regular “review and revise” of patients on antimicrobials
with a view to de-escalation (i.e. switching to “narrower
spectrum” agents and/or reducing the number of agents
prescribed, switching from intravenous to oral route,
shortening treatment duration or stopping antimicrobial
therapy). Strategies such as “Start Smart then Focus” in
the UK [4] and “Antibiotic Timeouts” in the USA [5]
utilise diagnostic information to support de-escalation
decisions made at around 48–72 h. Provision of timely
and reliable patient level diagnostic results to support
“review and revise” is one of the key ways in which
microbiology laboratories can contribute to antimicro-
bial stewardship [6]. However, while reductions in UK
National Health Service (NHS) antibiotic prescribing have
been achieved in primary care, hospital prescribing in-
creased by 7.7% in England between 2013 and 2017 [3].
The extent to which diagnostic microbiology informs
antimicrobial decision making in individual patients is
limited by pre-analytic factors (most notably whether
samples are taken), analytic factors (time, test perform-
ance) and post-analytic factors (reporting, interpretation).
There is a lack of evidence for which of these really
matters to inform strategies to maximise the impact of
diagnostic testing. We performed a patient level analysis
of diagnostic testing and prescribing practice in our
hospital to determine what impact diagnostic results have
on antimicrobial de-escalation decision making.
Methods
Antimicrobial prescriptions
Antimicrobial prescribing data for adult inpatients were ex-
tracted from routine pharmacy audits of prescribing quality
conducted across the Brighton and Sussex University
Hospitals NHS Trust (BSUH), from July 2016 to April
2017, excluding September 2016 when staff were unavail-
able. Sampling included acute, medical, surgical and inten-
sive care wards. Prescriptions were removed if they were
for topical agents, prophylactic use or if no unique patient
hospital identification (ID) was recorded (Fig. 1). Anti-
microbial indications were grouped into major categories:
respiratory, urinary, sepsis unclear source, skin and soft
tissue, abdominal, other, and not documented.
We grouped prescriptions into “Prescription Episodes”
(PEs), defined as one or more antimicrobials prescribed
for the same patient during the same time period for the
same illness (where the latter could be determined). For
example, amoxicillin and doxycycline treating pneumo-
nia would constitute a single PE; whereas a patient given
flucloxacillin, teicoplanin and clindamycin for osteomye-
litis and trimethoprim for an intercurrent urinary tract
infection (UTI) would count as two PEs (one for osteo-
myelitis, the other for UTI). Where no indication was
documented, prescriptions from the same patient were
assumed to be from separate admissions (and so count
as distinct PEs) if they were prescribed ≥ month apart.
Microbiology results
For each patient ID, microbiology results for blood,
urine, sputum or cerebrospinal fluid (CSF) samples sent
within +/− 7 days of the prescription date were pulled
from the hospital pathology system ‘Winpath’. Where
prescription dates were unrecorded, test results were
analysed for prescriptions from the same month or the 3
days at the start and end of the adjacent months. Micro-
biology results were considered ‘positive’ if clinically sig-
nificant growth of a recognised pathogen was recorded.
Otherwise, culture negative samples and cultures yield-
ing organisms likely to be contaminants were considered
‘negative’ (Fig. 1). Contaminants were initially flagged up
in the microbiologist comments section on the result
(also viewable by treating clinicians), and confirmed on
case review by authors SP and WLH.
A single CSF sample with no microorganism identified
on Gram stain or CSF culture was considered ‘positive’
due to significantly elevated CSF white cell count in an
intubated patient with external ventricular drain in situ
and new onset fever. We note that diagnosis and man-
agement of healthcare-associated ventriculitis is complex
[7]; as our study focused on decision making by anti-
microbial prescribers, we interpreted this CSF result in
the same way as the treating clinicians had done i.e. a
positive result suggesting bacterial ventriculitis.
Regarding microbiology testing methods at BSUH
during the study: the laboratory routinely used MALDI-
TOF identification for cultures that flagged positive fol-
lowing initial Gram stain. We did not assess the impact
of active surveillance cultures (e.g. swabs screening for
MRSA colonisation), and none of the antimicrobial pre-
scriptions in our dataset were for MRSA decolonisation
treatment.
Impact of diagnostic testing on antimicrobial prescription
review
We reviewed case records for all patients with positive
diagnostic results and a random sample of ~ 25% pa-
tients with negative results (randomisation was per-
formed in the R programming language). Reviews were
conducted by authors WLH and SP using paper medical
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Fig. 1 Flow chart of antimicrobial prescription filtering and linking to diagnostic microbiology. Of 840 prescriptions collected by pharmacists, samples were
excluded if they were prophylactic (n = 11; breakdown: 7 peri-operative or otherwise surgical and 4 medical), topical (n = 21), or lacking unique patient
hospital identification numbers, IDs (n = 426). The 382 remaining prescriptions were grouped into 276 “Prescription Episodes” (PEs) of antimicrobials given
for the same patient illness (see main text). Contemporaneous diagnostic microbiology from blood, urine, sputum or CSF were linked to prescriptions with
matching hospital IDs. Contaminants (as initially flagged up in the microbiologist comment on the result, then confirmed on case review by authors WLH
and SP) were transferred from “positive” to “negative” and a single CSF sample was moved from “negative” to “positive” due to elevated white cell count
without any microorganism identified. All PEs with positive pathogenic microbiology (n = 38) and a randomised sample of the 124 PEs with negative
microbiology (n = 44) were reviewed, with 9 PEs removed at this stage due to the linked microbiology sample being deemed irrelevant to the
antimicrobial prescription. This left a final set for detailed case review of 33 PEs with positive microbiology and 40 with negative microbiology
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notes, electronic discharge summaries and electronic test
results (blood tests, microbiology etc), with ambiguous
cases resolved through group discussion. Records were
excluded from further analysis if the microbiology result
was deemed irrelevant to the indication for antimicrobial
treatment (for example, doxycycline prescribed to treat
community acquired pneumonia, with a microbiology
urine sample sent for query UTI).
Data were collected on microbiology result documen-
tation in the medical records, involvement of infectious
disease and/or microbiology teams, antimicrobial pre-
scription review decisions, and the likelihood that the
microbiology result influenced prescribing decisions (see
Additional file 1). We defined antimicrobial “escalation”
as adding agent(s), changing to “broader” cover, switch-
ing from oral to intravenous, or lengthening treatment
duration; “de-escalation” was defined as the inverse of
these.
Statistics
All data manipulations and analyses were performed in
the programming language R and using the dplyr pack-
age. For important findings we quote exact binomial
95% confidence intervals (95%CI) and P-values, calcu-
lated using the R package binom.
Results
Antimicrobial prescriptions
After filtering (Fig. 1), 382 antimicrobial prescriptions
were grouped into 276 Prescription Episodes (PEs) from
264 patients. The vast majority of antimicrobial prescrip-
tions were antibacterials (376/382, 98%), with the remain-
der being antifungals (5/382, 1.3%) and antiviral (1/382,
0.3%). There were no antiretrovirals or anti-TB medica-
tions included. The majority of prescriptions were intra-
venous (245/382, 64%) and from general medical wards
(230/382, 60%) (Additional file 2: Tables S1–S4). The
most commonly prescribed antimicrobials were co-
amoxiclav (68/382, 18%), piperacillin-tazobactam (58/382,
15%) and amoxicillin (40/382, 11%). The most commonly
documented indications were respiratory (134/382, 35%),
urinary (51/382, 13%) and sepsis unclear source (51/382,
13%). 34/382 (8.9%) PEs were for “other” indications,
broken down into: osteomyelitis (n = 14), central nervous
system (CNS) infections (n = 7), endocarditis (n = 6), ear
nose & throat (ENT, n = 2), oesophageal candidiasis (n =
2), oral infections (n = 2) and septic arthritis (n = 1).
Antimicrobial indication and duration were docu-
mented in 92 and 80% of prescriptions for which audit
data were recorded, and complied with Trust guidelines
in 82 and 81%, respectively (after removing prescriptions
with incomplete pharmacy data collection, Additional
file 2: Table S5). Data on 72-h reviews were recorded for
290/382 (76%) prescriptions, of which the main outcomes
were continue (141/290, 37%), stop (76/290, 20%) and
intravenous to oral switch (47/290, 12%) (Additional file 2:
Table S6).
Diagnostic microbiology and impact on prescription
review
162/276 (59, 95%CI 53–65%) PEs had contemporaneous
microbiology results identified from the hospital path-
ology database. Where a prescription date was recorded,
there was a median of 2 days (interquartile range 1–4)
between the prescription and the microbiology sample
being taken. “Sepsis unclear source” was the most likely
indication to have microbiology sent (27/35, 77%), while
“skin and soft tissue” was least (14/34, 41%) (Table 1).
124/276 (45, 95%CI 39–51%) PEs had exclusively nega-
tive microbiology results; 21 had exclusively positive re-
sults and 17 had both positive and negative results,
which were analysed together as “positives”.
After removing positives with irrelevant microbiology,
33/276 (12, 95%CI 8.4–16%) of all PEs had a pathogenic
microbiological diagnosis available to guide prescribing
(Table 1), or 33/162 (20, 95%CI 14–27%) of PEs for
which any samples had been sent for testing. “Skin and
soft tissue” was the least likely indication to return rele-
vant positive microbiology (1/34, 3%), while “other” was
most likely (5/22, 21% - mainly driven by endocarditis,
osteomyelitis and CNS infections). Review of the medical
records for all 33 positives suggested that the microbiol-
ogy result affected the antimicrobial decision making in
20 PEs (7% of total, 61% of PEs with relevant positive
microbiology), but in only 6 PEs (2% of total, 18% of
positives) did the positive microbiology lead to anti-
microbials being “de-escalated” (Additional file 2: Ta-
bles S7–S8). Blood cultures and CSF, if positive, were
more likely to affect the antimicrobial regimen (15/16,
94% and 3/3, 100%, respectively) than urine or spu-
tum (1/9, 11% and 2/7, 29%, respectively) (Table 2).
Positive blood cultures had other impacts on clinical
management, such as prompting echocardiography to
exclude endocarditis.
Negative microbiology results were more common
(141/276, 51% (95% CI 45–57%) of PEs returning at least
1 negative result), but less likely to be documented and
rarely altered antimicrobial therapy. “Sepsis unclear
source” was the most likely indication to return only
negative microbiology (22/35, 63%) (Table 1). Of 40 ran-
domly sampled PEs with negative microbiology relevant
to the prescription, 9 (23%) had the result documented
in the medical records (compared with 27/33 (82%) for
PEs with relevant positive microbiology; P = 6.7 × 10− 6,
exact binomial test). In only 1 case did a negative result
unambiguously lead to antimicrobial de-escalation (stop-
ping ceftriaxone for meningitis following negative CSF
results).
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Discussion
We have evaluated the patient-level impact of diagnostic
microbiology on “review and revise” decision making in an
unselected cohort of antimicrobial prescriptions for adult
inpatients. Irrespective of indication, a substantial propor-
tion (~ 40%) of patients started on systemic antimicrobials
did not have diagnostic samples sent. This clearly limits the
potential role of diagnostic microbiology in guiding anti-
microbial review decisions. Where samples were sent, only
~ 20% yielded a significant positive result. Cultures may be
negative for many reasons including prior antibiotic expos-
ure in the patient, poor sampling technique, inadequate
sampling equipment, delays in reaching the laboratory and
insufficient test sensitivity for pathogen detection. While
positive blood and CSF cultures usually impacted patient
management, this often manifested as decisions to extend,
broaden or intensify antimicrobial therapy (such as adding
vancomycin after identifying Gram positive cocci in blood
cultures). In such cases, the microbiological result may have
been crucial for optimising patient therapy, but did not
contribute to antimicrobial de-escalation. Positive sputum
and urine cultures often did not significantly inform patient
management and generally did not contribute to antimicro-
bial de-escalation. Among 40 reviewed PEs with negative
microbiology we found only one instance in which the
negative result directly informed a de-escalation decision.
There is a lack of direct evidence that microbiological
test results support clinical decision making to limit
antibiotic exposure. Our data are consistent with studies
showing that cultures are often not taken from patients
with suspected infections [8], but demonstrate further
that when cultures are taken they still often fail to in-
form clinical decision making. The reasons why may
depend on the clinical scenario. Given a standard treat-
ment duration for lower UTI in women of 3 days, it is
likely that time is a key limitation: results are generally
available too late. Preliminary negative blood and spu-
tum culture results are routinely available at 48 h and so
the explanation here may be a lack of confidence in
negative results by treating clinicians. Ensuring adequate
equipment, technique and protocols are in place for col-
lecting microbiological samples (e.g. taking uncontamin-
ated blood cultures prior to administering antibiotics,
clean midstream urine capture etc) may improve their
diagnostic yield. However, even in the context of rando-
mised controlled trials only 30–40% of patients with sep-
sis are bacteraemic [9]. Prescriber behavioural factors
such as “prescribing etiquette” may also contribute to a
reluctance to stop antimicrobials [10].
Our study has several limitations. The data were col-
lected from a single centre; however, ours is a fairly typical
NHS acute hospital with no reason to believe patients
were selected in a biased way. We have focused on a spe-
cific, poorly studied, part of the pathway between diagnos-
tic sampling and clinical decision making i.e. the actions
based on the result taken by treating clinicians across a
broad range of inpatient ward settings. We have not
assessed whether the right patients are being sampled be-
yond the striking observation that 41% of patients started
on systemic antibiotics weren’t sampled. We have not
assessed quality of sampling e.g. blood culture taking and
handling. Date information was sometimes lacking, but by
allowing a +/− 7 day window we have if anything erred on
the side of overestimating use of diagnostic testing. We
have not assessed the impact of other microbiological
sample types such as skin and wound swabs, stool, re-
spiratory PCR or urinary pneumococcal antigen; but these
comprise a minority of samples and are unlikely to make a
substantial impact. Our findings are at odds with previous
studies reporting benefit in antimicrobial selection
through rapid microbiological identification with tech-
niques such as MALDI-TOF [11]. However, such studies
often fail to measure antibiotic de-escalation specifically,
with limited evidence on the interpretation of negative re-
sults by treating clinicians across hospitals. In addition,
antimicrobial therapy may initially get escalated following
positive Gram stains (e.g. to cover potentially resistant or-
ganisms), then de-escalated (narrowed spectrum) once full
antimicrobial susceptibility testing results become avail-
able, particularly for Gram negative pathogens [12],
Table 2 Impact of positive microbiology on antimicrobial prescribing for different microbiological sampling types
Microbiology
sample type
PE with relevant
positive micro
Positive micro result
documented*
Positive micro with
ID/micro team involved*
Positive micro where
Abx were affected*
Positive micro where
Abx were de-escalated*
Blood 16 16 (100%) 16 (100%) 15 (94%) 6 (38%)
Urine 9 5 (56%) 2 (22%) 1 (11%) 1 (11%)
Sputum 7 5 (71%) 4 (57%) 2 (29%) 0
CSF 3 3 (100%) 3 (100%) 3 (100%) 0
Total 35 29 (83%) 25 (71%) 21 (60%) 7 (20%)
Table shows the Prescription Episodes (PEs, defined in main text) with positive diagnostic microbiology broken down by microbiological sampling type (blood,
urine, sputum, cerebrospinal fluid (CSF)). Compared with urine or sputum, positive blood and CSF cultures were more likely to be documented in the medical
records, to have infectious diseases and/or microbiology teams involved, and to result in the antimicrobial regimen being altered (P<10-4 for pairwise comparisons
between blood cultures and urine or sputum cultures, exact binomial test after Bonferroni correction for multiple comparisons). ID Infectious Diseases team, ABx
Antimicrobials; * = Denominator for all cases is the “PE with relevant positive micro” column. Note that 33 PEs had significant positive microbiology; the total
shown of 35 is because two patients had two positive culture types (blood and urine or blood and sputum) and these were counted separately for this table
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making it harder to summarise the net effect on anti-
microbial exposure. We do not take account of antimicro-
bials that were never started due to negative microbiology
results, which may be relevant in UTIs. Lastly we do not
address the separate important role of diagnostic micro-
biology around screening for carriage of specific patho-
gens such as Carbapenem resistant Enterobacteriaceae
(CRE) since our study focused on treatment rather than
infection control practice. Of note none of these issues
undermines our fundamental observation that in the ma-
jority of instances negative microbiology does not lead to
clinicians stopping a patient’s antibiotic treatment.
Conclusion
In conclusion, the impact of diagnostic microbiology in
guiding antimicrobial de-escalation and reducing anti-
microbial exposure on an individual patient level across
hospital wards is currently limited. Our data suggest that
an important reason is the perceived lack of predictive
value for negative results by treating clinicians. For positive
results, faster availability of antimicrobial susceptibility test-
ing may also be impactful to limit unnecessary exposure to
escalated empirical therapy. Negative microbiology is only
part of the multifactorial assessment required for making
antimicrobial de-escalation decisions, alongside patient fac-
tors, biochemistry and treatment response. Increasing the
contribution of diagnostic microbiology to antimicrobial
stewardship requires improvement in the actual and per-
ceived negative predictive value of diagnostic testing.
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